NASDAQ:AXSM

Axsome Therapeutics Stock Forecast, Price & News

$52.99

-1.10 (-2.03 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$52.84

Now: $52.99▼

$54.57

50-Day Range

$54.09

MA: $63.92▼

$72.27

52-Week Range

$52.84

Now: $52.99▼

$109.53

Volume271,031 shs

Average Volume304,024 shs

Market Capitalization$1.98 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.59

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AXSM

Previous Symbol

CUSIPN/A

CIK1579428

Webaxsome.com

Phone212-332-3241

Employees60

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.36

Current Ratio9.99

Quick Ratio9.99

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.18 per share

Price / Book10.23

Profitability

EPS (Most Recent Fiscal Year)($2.01)

Net Income$-68,350,000.00

Net MarginsN/A

Return on Equity-62.33%

Return on Assets-47.87%

Miscellaneous

Outstanding Shares37,405,000

Market Cap$1.98 billion

Next Earnings Date5/14/2021 (Estimated)

OptionableOptionable

Headlines

Axsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week Low at $53.63
April 8, 2021 | americanbankingnews.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Brokerages
April 4, 2021 | americanbankingnews.com

Zacks: Brokerages Anticipate Axsome Therapeutics, Inc. (NASDAQ:AXSM) to Announce -$0.71 Earnings Per Share
April 1, 2021 | americanbankingnews.com

Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?
March 31, 2021 | finance.yahoo.com

Oversold Conditions For Axsome Therapeutics
March 30, 2021 | nasdaq.com

Read This Before Selling Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares
March 30, 2021 | finance.yahoo.com

Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down to $63.53
March 24, 2021 | americanbankingnews.com

1 Green Flag for Axsome Therapeutics
March 11, 2021 | finance.yahoo.com

InvestorNewsBreaks - Axsome Therapeutics, Inc. (NASDAQ: AXSM) Featured in Mizuho Securities Research Report
March 5, 2021 | marketwatch.com

Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
March 2, 2021 | finance.yahoo.com

Axsome Therapeutics, Inc. (AXSM) Q4 2020 Earnings Call Transcript
March 1, 2021 | finance.yahoo.com

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 1, 2021 | finance.yahoo.com

Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
February 16, 2021 | finance.yahoo.com

Forget Bitcoin: This Biotech Stock Is a Better Buy in 2021
February 10, 2021 | finance.yahoo.com

Axsome Therapeutics (AXSM) Shares Cross Above 200 DMA
February 4, 2021 | nasdaq.com

AXSM Feb 2021 55.000 put
January 30, 2021 | ca.finance.yahoo.com

AXSM Feb 2021 80.000 call
January 30, 2021 | ca.finance.yahoo.com

AXSM Feb 2021 87.500 put
January 29, 2021 | ca.finance.yahoo.com

AXSM Feb 2021 77.500 call
January 29, 2021 | ca.finance.yahoo.com

Is It Too Late to Get In On This Millionaire-Making Stock?
January 27, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.39 out of 5 stars

Medical Sector

664th out of 2,010 stocks

Pharmaceutical Preparations Industry

321st out of 769 stocks

3.4 Analyst's Opinion

Consensus Rating
Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $146.90, Axsome Therapeutics has a forecasted upside of 177.2% from its current price of $52.99.
Amount of Analyst Coverage
Axsome Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Axsome Therapeutics has received 355 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Axsome Therapeutics has received 294 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Axsome Therapeutics has received 54.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote “Outperform” if you believe AXSM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Axsome Therapeutics does not currently pay a dividend.
Dividend Growth
Axsome Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 26.00% of the stock of Axsome Therapeutics is held by insiders.
Percentage Held by Institutions
63.64% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Axsome Therapeutics are expected to decrease in the coming year, from ($2.65) to ($3.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axsome Therapeutics is -19.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axsome Therapeutics is -19.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axsome Therapeutics has a P/B Ratio of 10.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$52.99

-1.10 (-2.03 %)

(As of 04/9/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

Is Axsome Therapeutics a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 sell rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Axsome Therapeutics stock.
View analyst ratings for Axsome Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Axsome Therapeutics?

Wall Street analysts have given Axsome Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axsome Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Axsome Therapeutics.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Sunday, February, 28th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.05.
View Axsome Therapeutics' earnings history.

How has Axsome Therapeutics' stock been impacted by COVID-19?

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AXSM stock has decreased by 28.1% and is now trading at $52.99.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AXSM?

12 equities research analysts have issued 12 month target prices for Axsome Therapeutics' shares. Their forecasts range from $66.00 to $210.00. On average, they anticipate Axsome Therapeutics' share price to reach $146.90 in the next year. This suggests a possible upside of 177.2% from the stock's current price.
View analysts' price targets for Axsome Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the following people:

Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 53, Pay $761.25k)
Mr. Nick Pizzie CPA, M.B.A., Chief Financial Officer (Age 46, Pay $520k)
Mr. Mark L. Jacobson, COO & Sec. (Age 38)
Dr. Cedric O'Gorman M.B.A., M.D., MBA, Sr. VP of Medical Affairs (Age 45)
Dr. Amanda Jones Pharm.D., Sr. VP of Clinical Devel. (Age 37)
Ms. Lori Englebert, Sr. VP of Commercial & Bus. Devel.
Mr. Kevin Laliberte Pharm.D., Exec. VP of Product Strategy (Age 43)
Joseph Debrah-Afful CPA, M.B.A., Director of Fin.

Who are some of Axsome Therapeutics' key competitors?

Some companies that are related to Axsome Therapeutics include Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), TG Therapeutics (TGTX), Evotec (EVTCY), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), Galapagos (GLPG), Atea Pharmaceuticals (AVIR) and Sage Therapeutics (SAGE).
View all of AXSM's competitors.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baldwin Brothers Inc. MA (0.07%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie.
View institutional ownership trends for Axsome Therapeutics.

Which major investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers Inc. MA.
View insider buying and selling activity for Axsome Therapeutics or view top insider-selling stocks.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $52.99.

How much money does Axsome Therapeutics make?

Axsome Therapeutics has a market capitalization of $1.98 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

Axsome Therapeutics employs 60 workers across the globe.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is axsome.com.

Where are Axsome Therapeutics' headquarters?

Axsome Therapeutics is headquartered at 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241.

This page was last updated on 4/11/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here